Benzinga · Mar 26, 2026
HC Wainwright & Co. Maintains Buy on Insmed, Raises Price Target to $245
HC Wainwright & Co. analyst Andrew S. Fein maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $230 to $245.
IN
NASDAQ · INSM
Insmed Incorporated
Healthcare · Medical - Pharmaceuticals
$120.00
Down-$3.98 (-3.21%)
Updated Sep 20, 2026, 3:39 PM
SID Score
6.2/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 41.63B
- P/E ratio
- -34.92
- Dividend yield
- 0.00%
- 52-week range
- $90.39 – $212.75
- Volume
- 3.45M
- Avg. volume
- 2.37M
Price performance
INSM price history
1M range · 0 trading sessions · Daily adjusted prices
INSM does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest INSM news
The latest Smart Investors Daily articles mentioning INSM.
Stock researchCompany · Overview
INSM research
Overview
Company profile and research snapshot.
Company profile
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $226.67
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | Roth Capital | Buy | — |
| Aug 10, 2026 | Truist Securities | Buy | — |
| Aug 10, 2026 | JP Morgan | Overweight | — |
| Aug 7, 2026 | Evercore ISI Group | Outperform | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Mar 26, 2026
Liquidia: Yutrepia Has Impressed, But Here's Why I Remain Cautious (Rating Upgrade)
Yutrepia's initial commercialization impresses, but mounting competitive threats cloud long-term prospects for Liquidia. See why LQDA stock is upgraded to hold.
SeekingAlpha · Mar 25, 2026
Insmed Incorporated (INSM) Shareholder/Analyst Call - Slideshow
2026-03-25. The following slide deck was published by Insmed Incorporated in conjunction with this event.
Yahoo · Mar 25, 2026
Insmed CEO reveals Japan patient population exceeds US market for lung disease
Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more patients with MAC lung disease than the entire United States. That came directly from CEO Will Lewis in a recent interview. “There are actually more patients in Japan that have this disease than there ... Insmed CEO reveals Japan patient population exceeds US market for lung disease
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
